• Mashup Score: 7

    Objective To evaluate the dose-response relationship of 10, 20, and 40 mg ponesimod and long-term efficacy and safety of ponesimod 20 mg using an analysis of combined data from the phase 2 Core and Extension studies in patients with relapsing-remitting multiple sclerosis (RRMS). Methods In the Core study, 464 patients were randomized (1:1:1:1): placebo (n = 121), 10 mg (n = 108), 20 mg (n =…

    Tweet Tweets with this article
    • Long-term Treatment With #Ponesimod in Relapsing-Remitting #MultipleSclerosis: Results From Randomized Phase 2b Core and Extension Studies https://t.co/DSGdSnsEck #NeuroTwitter #MS https://t.co/XSJ5kdWPEq

  • Mashup Score: 2

    The selective sphingosine-1-phosphate receptor 1 modulator for adults with relapsing forms of MS proved superior to teriflunomide in a phase 3, 2-year, head-to-head comparative study.

    Tweet Tweets with this article
    • FDA clears #ponesimod for relapsing MS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. https://t.co/2Tyz9b8dg6